Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548876 | 0.92 | KMT2A (0.38) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL549746 | 0.88 | KMT2A (0.33) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL548667 | 0.86 | HDAC11 (0.35) | KMT2AMEN1LMNAHDAC11 | |
| SCHEMBL548493 | 0.85 | HDAC11 (0.30) | HDAC11 | |
| SCHEMBL549103 | 0.84 | KMT2A (0.38) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL549889 | 0.84 | MEN1 (0.31) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL547739 | 0.84 | KMT2A (0.39) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL549028 | 0.82 | HDAC11 (0.31) | HDAC11 | |
| SCHEMBL549833 | 0.81 | KMT2A (0.37) | KMT2AMEN1POLBGAAGFER | |
| SCHEMBL548900 | 0.81 | KMT2A (0.32) | KMT2AMEN1LMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110614-B2 | Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2090563-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | ARCN1, RTN3, CHRNA3 | KMT2A 3737/4885MEN1 3412/4885POLB 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.